ASTHAstrana Health, Inc.
Astrana Health, Inc. (ASTH) provides managed care services, primarily through Accountable Care Organizations (ACOs), which deliver cost-effective, high-quality care to Medicare beneficiaries. The next catalyst is Sep 24, 2026 — Astrana Health stock tumbles after short report. This event will test the company’s ability to defend its valuation in the face of short-term earnings pressure and macroeconomic uncertainty.
- Revenue grew 56.4% YoY to $3.55B in the second quarter of 2026, driven by strong ACO performance.
- Net margin (TTM) stands at 1.2%, reflecting the sector’s thin profit margins.
- Debt-to-equity ratio of 0.31x suggests a relatively conservative capital structure.
The Read
Astrana Health's stock showed little reaction to the CMS 2027 Medicare Advantage rates aligning with expectations and only a slight 0.
The schedule
- Thu15Oct
2027 Medicare Advantage Annuity Proposal
- Fri6Nov
- Fri5Feb
- Thu18Feb
CMS 2028 Advance Notice Publication
- Mon5Apr
CMS 2028 Final Rate Announcement
- Fri7May
- Thu3Jun
Astrana Health, Inc. to Participate in Upcoming Investor Conferences
- Fri6Aug
Past
- Thu24Sep
Astrana Health stock tumbles after short report
- Fri7Aug
Actual outcome: Bull · $37.97 at outcome
Astrana Health delivered strong first-quarter results, reporting better-than-expected trends across medical costs, free cash flow, and revenue. The stock rallied as these positive fundamentals, along with news that the Prospect acquisition is ahead of schedule, reassured investors that the company can sustain its growth trajectory without compromising margins.
- Fri8May
Actual outcome: Mixed · $39.01 at outcome
Astrana Health reported strong Q1 results, surpassing earnings and revenue estimates, with management highlighting that its Prospect acquisition integration is ahead of schedule. Despite these positive fundamental updates and stronger-than-expected trends in medical costs and free cash flow, the stock's reaction was muted, falling just 0.7% by the outcome date.
- Mon6Apr
Actual outcome: Bull · $27.41 at outcome
The CMS finalized the 2027 Medicare Advantage reimbursement rates largely in line with its earlier advance notice, avoiding unexpected cuts but lacking any major upside surprises. The stock remained flat as the finalized base rates and risk adjustment models offered no new catalysts, confirming the market's existing expectations for the regulatory environment.